Ropeginterferon alfa-2b versus standard therapy for low-risk patients with polycythemia vera. Final results of Low-PV randomized phase II trial

After one year of treatment with ropeginterferon alfa-2b, 52 patients (81%) with low-risk polycythemia vera maintained median hematocrit values ≤45% over 12 months, in the absence of progressive disease, compared with 32 patients (51%) receiving standard therapy with phlebotomy and low-dose aspirin (P < 0.001). Further data from the randomized phase 2 Low-PV trial, presented during the 2022 American Society of Hematology Annual Meeting, demonstrated that among these responding patients, 83% and 59%, respectively, achieved complete response to treatment after 24 months.